ChemoCentryx Financial Statements (CCXI)
|
|
|
|
Report date
|
|
|
12.03.2018 |
11.03.2019 |
10.03.2020 |
01.03.2021 |
01.03.2022 |
|
08.08.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
82.5 |
42.9 |
36.0 |
64.9 |
32.2 |
|
37.5 |
|
Operating Income, bln rub |
|
|
16.5 |
-40.3 |
-58.3 |
-55.2 |
-134.5 |
|
-136.2 |
|
EBITDA, bln rub |
? |
|
18.3 |
-36.2 |
-51.7 |
-51.9 |
-131.3 |
|
-131.9 |
|
Net profit, bln rub |
? |
|
17.9 |
-38.0 |
-55.5 |
-55.4 |
-129.1 |
|
-129.5 |
|
|
OCF, bln rub |
? |
|
4.88 |
16.4 |
-70.1 |
-81.1 |
-75.6 |
|
-53.5 |
|
CAPEX, bln rub |
? |
|
0.723 |
0.838 |
0.790 |
15.4 |
19.0 |
|
5.47 |
|
FCF, bln rub |
? |
|
4.16 |
15.6 |
-70.9 |
-96.6 |
-94.6 |
|
-59.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
66.0 |
83.1 |
94.3 |
120.1 |
162.1 |
|
168.2 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.302 |
|
1.31 |
|
R&D, bln rub |
|
|
49.5 |
62.7 |
70.3 |
77.9 |
83.0 |
|
70.6 |
|
Interest expenses, bln rub |
|
|
0.004 |
1.22 |
2.15 |
2.64 |
2.70 |
|
6.60 |
|
|
Assets, bln rub |
|
|
189.3 |
183.3 |
209.1 |
518.9 |
425.7 |
|
419.4 |
|
Net Assets, bln rub |
? |
|
79.3 |
14.7 |
66.0 |
385.6 |
286.1 |
|
236.5 |
|
Debt, bln rub |
|
|
91.9 |
168.6 |
21.3 |
25.2 |
4.72 |
|
72.0 |
|
Cash, bln rub |
|
|
127.3 |
177.0 |
172.8 |
436.6 |
264.5 |
|
328.6 |
|
Net debt, bln rub |
|
|
-35.3 |
-8.40 |
-151.5 |
-411.3 |
-259.8 |
|
-256.6 |
|
|
Ordinary share price, rub |
|
|
5.95 |
10.9 |
39.6 |
61.9 |
36.4 |
|
51.9 |
|
Number of ordinary shares, mln |
|
|
48.4 |
49.8 |
56.9 |
65.7 |
65.7 |
|
71.2 |
|
|
Market cap, bln rub |
|
|
288 |
543 |
2 250 |
4 067 |
2 392 |
|
3 696 |
|
EV, bln rub |
? |
|
253 |
535 |
2 099 |
3 656 |
2 132 |
|
3 440 |
|
Book value, bln rub |
|
|
79 |
15 |
66 |
386 |
286 |
|
237 |
|
|
EPS, rub |
? |
|
0.37 |
-0.76 |
-0.98 |
-0.84 |
-1.96 |
|
-1.82 |
|
FCF/share, rub |
|
|
0.09 |
0.31 |
-1.25 |
-1.47 |
-1.44 |
|
-0.83 |
|
BV/share, rub |
|
|
1.64 |
0.30 |
1.16 |
5.87 |
4.36 |
|
3.32 |
|
|
EBITDA margin, % |
? |
|
22.2% |
-84.5% |
-143.8% |
-80.0% |
-407.5% |
|
-351.6% |
|
Net margin, % |
? |
|
21.6% |
-88.6% |
-154.3% |
-85.3% |
-400.5% |
|
-345.2% |
|
FCF yield, % |
? |
|
1.44% |
2.87% |
-3.15% |
-2.37% |
-3.96% |
|
-1.60% |
|
ROE, % |
? |
|
22.5% |
-257.6% |
-84.1% |
-14.4% |
-45.1% |
|
-54.8% |
|
ROA, % |
? |
|
9.43% |
-20.7% |
-26.5% |
-10.7% |
-30.3% |
|
-30.9% |
|
|
P/E |
? |
|
16.1 |
-14.3 |
-40.6 |
-73.5 |
-18.5 |
|
-28.5 |
|
P/FCF |
|
|
69.3 |
34.8 |
-31.7 |
-42.1 |
-25.3 |
|
-62.7 |
|
P/S |
? |
|
3.49 |
12.7 |
62.6 |
62.7 |
74.2 |
|
98.5 |
|
P/BV |
? |
|
3.63 |
36.9 |
34.1 |
10.5 |
8.36 |
|
15.6 |
|
EV/EBITDA |
? |
|
13.8 |
-14.8 |
-40.6 |
-70.4 |
-16.2 |
|
-26.1 |
|
Debt/EBITDA |
|
|
-1.93 |
0.23 |
2.93 |
7.92 |
1.98 |
|
1.95 |
|
|
R&D/CAPEX, % |
|
|
6 846% |
7 486% |
8 896% |
505.4% |
436.3% |
|
1 290% |
|
|
CAPEX/Revenue, % |
|
|
0.88% |
1.95% |
2.20% |
23.7% |
59.0% |
|
14.6% |
|
| ChemoCentryx shareholders |
